Fibroblast growth factor 23 is associated with risk of intracerebral hemorrhage
European Journal of Neurology, 2021
Svensson E., Söderholm M.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
CVD | Patient Stratification | Plasma |  Olink Target 96 |
Abstract
Background and purpose
Fibroblast growth factor 23 (FGF23) is an osteogenic hormone associated with chronic kidney disease and is an emerging risk factor for several cardiovascular diseases. The association of FGF23 with stroke is unclear. The aim of this study was to investigate the association of FGF23 with incident intracerebral hemorrhage (ICH).
Methods
This was a nested case–control study of 220 ICH cases and 244 age‐ and sex‐matched controls from the population‐based Malmö Diet and Cancer Study (n = 28,449). Incident ICH cases were ascertained using national registers and classified by bleeding location. Logistic regression was used to study the association of plasma levels of FGF23 with incident ICH, adjusting for potential ICH risk factors. Subgroup analyses were performed for lobar and non‐lobar ICH, fatal ICH, ICH with large volume and ICH with poor functional outcome, respectively.
Results
Higher FGF23 levels at baseline were significantly associated with incident ICH. After multivariable adjustment, the odds ratio for the association with all ICH was 1.84 (95% confidence interval [CI] 1.25–2.71, p = 0.002) per doubling of FGF23 concentration. For lobar and non‐lobar ICH, odds ratios were 1.73 (95% CI 1.04–2.87, p = 0.035) and 2.13 (95% CI 1.32–3.45, p = 0.002), respectively. FGF23 was also significantly associated with fatal ICH, ICH with large volume and ICH with poor functional outcome.
Conclusions
Higher FGF23 was associated with incident ICH in this nested case–control study. Further studies are required to explore whether the association is causal.